葛兰素史克公司的创新挑战赛收到了400多申请，其中14项涉及抗感染、癌症、神经退行性疾病领域的提议脱颖而出。
由GSK DPAc（学术研发合作部）部门主持的快速审核通道研发竞赛始于2011年，旨在帮助追踪有前途的项目。
此项竞赛去年在北美首次推出，计划将在2014年扩展至欧洲，预计将设立20个奖项。
2014年的获奖者包括北美的五支学术团队和欧洲的9支团队，GSK指出，“因为他们的工作贯彻推进了尚未满足的医疗需求，所以斩获此奖。”
获奖者可获得与葛兰素史克DPAc及分子研发团队的合作机会，可访问GSK公司的化合物库以及GSK科学家们确定的候选药物库。
由于当下研发部内部被广泛运用的老方法的缓慢低效，制药公司越来越注重对学术研究人员所做工作的挖掘方式。
其他公司如阿斯利康和默克也部署了方法应对研发创新挑战。与此同时，强生公司采取了稍有不同的策略，在前沿学术中心旁的旁开放网络办公平台，为外部研究团队提供专业知识和帮助。
剑桥大学教授Lever在艾滋病治疗领域的提议在此次挑战赛中胜出，他表示，“认真、妥善地去做，加快些速度，参加了‘快速审核通道研发竞赛’后下一阶段就是帮助研究向前发展。”
许多参赛项目都已经开始开展实际工作了，GSK预计将在2015年年中完成首轮化合物筛选。
DPAc的欧洲区主管Holmes称，“我们认为学术界和产业界结合有一个真正的优势是帮助药物发现领域的创新想法能向前发展。”“我们期待与每个获奖者一起帮助发现新的有质量的药物活性化合物。”
以下是全部获奖者名单：
欧洲 |
|
|
Chatziantoniou博士，国家卫生和医学研究所：肾脏疾病 |
Furga教授和Huber博士，分子医学研究中心：肿瘤 |
|
|
Geerten博士，德比大学医学中心：治疗血管渗漏和水肿 |
|
|
Burnett博士，梅奥诊所；Malany博士，桑福德伯翰医学研究所：发现抗高血压药物 |
Murphy教授，威斯塔研究所；George教授和Leu教授，宾夕法尼亚大学：肿瘤 |
Sperandio教授，德克萨斯大学西南医学中心：细菌感染靶向研究 |
Strack教授，爱荷华大学：神经保护的线粒体碎片靶向研究 |
|
GlaxoSmithKline's innovation challenge attracted more than 400 applications this year, with 14 proposals seleced in areas including anti-infectives, cancer and neurodegenerative diseases.
The Discovery Fast Track competition is run by a GSK department known as DPAc - Discovery Partnerships with Academia - which was set up in 2011 and aims to help track down promising projects.
First launched in North America last year, the Challenge was extended to Europe in 2014 and had been expected to provide up to 20 awards.
2014's crop of winners includes five academic teams from North America and nine teams from Europe whose projects were seleced "because they hold the promise of advancing unmet medical needs," said GSK.
The winners get the opportunity to collaborate with the DPAc and Molecular Discovery Research teams at GSK, with access to the company's compound collection as well as input from GSK scientists on the identification of suitable drug candidates.
Pharma is increasingly looking at ways in which it can tap into the work being done by academic researchers, as it is now widely accepted that the old ways of doing all R&D in-house is slow and inefficient.
Other companies that have deployed the innovation challenge approach include AstraZeneca (AZ) and Merck & Co. Meanwhile, firms such asJohnson & Johnson have taken a slightly different tack, opening a network of offices near leading academic centres and offering expertise and assistance to external research teams.
Professor Andrew Lever of the University of Cambridge - whose proposal in the area of HIV treatment was selected as a winner in the challenge - said: "To do this seriously and properly, and with some speed, entering the [Discovery Fast Track Challenge] was the logical next stage to help move the research forward."
Work on many of the winning projects has already started and GSK expects the first compound screens to be completed by mid-2015.
"We believe there is a real advantage in bringing together the best in academia and industry to help take innovative ideas forward in drug discovery," said DPAc's European head Duncan Holmes.
"We look forward to working with each of the winners to help identify novel quality pharmacologically active compounds for their targets."
The full list of winners is as follows:
Europe |
Dr Federica Briani, University of Milan: targeting bacterial infections |
Professor Morris Brown, University of Cambridge: primary hyperaldosteronism |
Dr Christos Chatziantoniou, National Institute of Health and Medical Research: kidney disease |
Professor Giulio Superti-Furga and Dr Kilian Huber, Research Center for Molecular Medicine: oncology |
Professor Steve Jackson and Dr Delphine Larrieu, University of Cambridge: inherited laminopathies |
Professor Andrew Lever, University of Cambridge: targeting HIV infection |
Professor Michael Marber, King's College London: ischaemic heart disease |
Dr Geerten P. van Nieuw Amerongen, VU University Medical Center: treatment of vascular leakage and oedema |
Dr Simon D. Wagner, University of Leicester: oncology |
North America |
Dr John Burnett Jr., Mayo Clinic, and Dr Siobhan Malany, Sanford-Burnham Institute for Medical Research: discovery of anti-hypertensive agents |
Professor Maureen Murphy, the Wistar Institute, and Professor Donna George and Professor Julia Leu, University of Pennsylvania: oncology |
Professor Vanessa Sperandio, University of Texas Southwestern Medical Center: targeting bacterial infections |
Professor Stefan Strack, University of Iowa: targeting mitochondrial fragmentation for neuroprotection |
Professor Tania Watts, University of Toronto: treatment of B-cell lymphomas
|
|手机版|药群论坛
( 蜀ICP备15007902号 )
收藏
支持
反对
楼主